Venus Remedies Limited has informed the Exchange regarding Appointment of Manu Chaudhary as Whole Time Director of the company w.e.f. October 01, 2026.
VENUSREM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
The filing covers Venus Remedies Limited's Board meeting outcomes. Key item: Appointment of Manu Chaudhary (related to Promoter family, holds 15,68,000 shares) as Whole Time Director effective October 1, 2026, subject to shareholder approval at the 37th AGM on August 20, 2026. Additionally, Mr. Saransh Chaudhary and Dr. (Mrs.) Savita Gulia were reappointed/appointed as Independent Directors for 5 years each. The company reported strong FY2026 standalone revenue of Rs. 768.73 Crores (up 19% from Rs. 644.47 Crores) and consolidated net profit of Rs. 102.78 Crores (up 127% from Rs. 45.31 Crores). EPS grew to Rs. 76.89 per share from Rs. 33.89. Board recommended final dividend of Rs. 10 per share (100%). New MOA/AOA adoption to align with Companies Act 2013 was also approved.
Strong financial performance with near-doubling of profits is positive for shareholders. The appointment of a promoter family member as Whole Time Director, along with family-related appointments, increases concentration in promoter hands, which raises governance considerations. Dividend and profit growth are stock-price supportive.